BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.

Prognosis of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma has improved since the introduction of highly active antiretroviral therapy.

Burkitt lymphomas (BLs) still have poor outcome in patients with bone marrow (BM) or central nervous system (CNS) involvement when treated with standard-dose chemotherapy.

We have prospectively evaluated the LMB86 regimen in 63 human immunodeficiency virus (HIV)-infected patients with stage IV (BM and/or CNS involvement) BL consecutively recruited between November 1992 and January 2006.

At BL diagnosis, the median CD4 cell count was 239 x 10(6)/L (range, 16-1188 x 10(6)/L).

Seven treatment-related deaths occurred and all patients experienced severe BM toxicity.

We conclude that LMB86 regimen is highly effective in advanced HIV-related BL and should be proposed for patients with CD4 count higher than 200 x 10(6)/L or ECOG of 2 or less.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17609431.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?

Trimodal or bimodal age-specific incidence rates for Burkitt lymphoma (BL) were observed in the United States general population, but the role of immunosuppression could not be excluded.

Incidence rates, rate ratios, and 95% confidence intervals for BL and other non-Hodgkin lymphoma (NHL), by age and CD4 lymphocyte count categories, were estimated using Poisson regression models using data from the United States HIV/AIDS Cancer Match study (1980-2005).

BL incidence was 22 cases per 100 000 person-years and 586 for non-BL NHL.

Adjusted BL incidence rate ratio among males was 1.6× that among females and among non-Hispanic blacks, 0.4× that among non-Hispanic whites, but unrelated to HIV-transmission category.

Non-BL NHL incidence increased from childhood to adulthood; in contrast, 2 age-specific incidence peaks during the pediatric and adult/geriatric years were observed for BL.

Non-BL NHL incidence rose steadily with decreasing CD4 lymphocyte counts; in contrast, BL incidence was lowest among people with ≤ 50 CD4 lymphocytes/μL versus those with ≥ 250 CD4 lymphocytes/μL (incidence rate ratio 0.3 [95% confidence interval = 0.2-0.6]).

The bimodal peaks for BL, in contrast to non-BL NHL, suggest effects of noncumulative risk factors at different ages.

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]

[Cites] Blood. 1999 Feb 1;93(3):1124 [10025990.001]

[Cites] Cancer. 1957 Sep-Oct;10(5):1045-54 [13472655.001]

[Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]

[Cites] Oncologist. 2006 Apr;11(4):375-83 [16614233.001]

[Cites] MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92 [16741494.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]

[Cites] Immunity. 2007 Aug;27(2):190-202 [17723214.001]

[Cites] AIDS. 2007 Nov 12;21(17):2265-70 [18090274.001]

[Cites] Int J Cancer. 2008 Dec 1;123(11):2658-63 [18767045.001]

[Cites] Int J Cancer. 2009 Apr 1;124(7):1497-502 [19089924.001]

[Cites] Int J Cancer. 2009 Apr 15;124(8):1745-55 [19165855.001]

[Cites] Curr Opin HIV AIDS. 2009 May;4(3):183-7 [19532048.001]

[Cites] PLoS Med. 2009 Jul 7;6(7):e1000107 [19582166.001]

[Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]

[Cites] Semin Cancer Biol. 2009 Dec;19(6):347-50 [19607918.001]

[Cites] Int J Cancer. 2010 Apr 1;126(7):1732-9 [19810101.001]

[Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]

[Cites] Am J Med. 2001 Dec 15;111(9):704-11 [11747850.001]

[Cites] Ann Intern Med. 1969 Apr;70(4):817-32 [4306129.001]

[Cites] J Biol Chem. 1999 Jun 25;274(26):18470-6 [10373455.001]

[Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]

[Cites] Eur J Cancer. 1972 Jun;8(3):305-8 [4677829.001]

[Cites] J Natl Cancer Inst. 1974 May;52(5):1397-401 [4406651.001]

[Cites] IARC Sci Publ. 1985;(60):217-24 [4065946.001]

[Cites] MMWR Morb Mortal Wkly Rep. 1987 Dec 25;36 Suppl 7:1S-20S [2826984.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9838-42 [1682922.001]

[Cites] Nature. 1993 Mar 25;362(6418):355-8 [8455722.001]

[Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]

[Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]

[Cites] Stat Med. 1995 Mar 15-Apr 15;14(5-7):491-8 [7792443.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6577-81 [7604036.001]

[Cites] Prev Med. 1995 Jul;24(4):375-7 [7479628.001]

[Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]

[CommentIn] Blood. 2010 Dec 16;116(25):5435-6 [21163931.001]

(PMID = 20813897.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CP / N02CP31003; United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Other-IDs] NLM/ PMC3031406

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma.

Treatment of AIDS-related malignant lymphoma (ARL) remains a therapeutic challenge.

We report the case of a 38-year-old man with advanced HIV-1 infection, pulmonary tuberculosis and Burkitt's lymphoma.

Six months later, the patient achieved not only a complete remission of Burkitt's lymphoma and sustained viral suppression, but also a full recovery from tuberculosis.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Antitubercular Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

[MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / drug therapy. Adult. Humans. Male. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15670254.001).

[ISSN] 1464-2662

[Journal-full-title] HIV medicine

[ISO-abbreviation] HIV Med.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antitubercular Agents

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma.

This study aims to describe 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) findings in patients with AIDS-related Burkitt lymphoma, at various times of treatment, and to define its utility for a better patient management.

We retrospectively studied 13 consecutive HIV-positive patients with Burkitt lymphoma who underwent one or more PET/CT.

Lymph node involvement, which is known to be uncommon in endemic or sporadic Burkitt lymphoma, was present in 54% of patients.

Additionally, in 3 patients, Burkitt lymphoma was predominantly located in parotid lymph nodes, which is also an unusual finding.

A negative scan was encountered in 3 of 10 patients imaged during treatment and in 1 of 4 patients imaged after treatment completion and was always associated with lasting complete remission.

Presence of residual area of uptake was related to both favorable and unfavorable outcome whether performed during treatment (5/7 and 2/7, respectively) or after (1/3 and 2/3, respectively).

Areas of increased uptake could be observed in lung (4 cases) or esophagus (3 cases), and were clinically related to pneumonia or esophagitis.

We recommend PET/CT for accurate initial staging of patients with AIDS-related Burkitt lymphoma.

Furthermore, PET/CT appears to have prognostic value, as a negative scan was always associated with a favorable outcome.

[MeSH-major] Burkitt Lymphoma / diagnosis. Fluorodeoxyglucose F18. Lymphoma, AIDS-Related / diagnosis. Radiopharmaceuticals

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18793085.001).

[ISSN] 1557-7449

[Journal-full-title] AIDS patient care and STDs

[ISO-abbreviation] AIDS Patient Care STDS

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related Burkitt lymphoma--a heterogeneous disease?

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis. Submandibular Gland Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18472158.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Viral; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.

BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.

In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.

Kaposi's sarcoma (KS) lesions are now causally associated with KSHV/HHV-8 but whether African ARL shows this association is not clear.

Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.

OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.

The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.

Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.

These findings were not related to age, sex or type of lymphoma.

There was no association of HHV-8 with the lymphoma cells.

CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.

[MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology

[MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]

[Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]

[Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]

[Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]

[Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]

[Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]

[Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]

[Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]

[Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]

[Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]

[Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]

[Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]

[Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]

[Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]

[Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]

[Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]

[Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]

[Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]

[Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]

[Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]

[Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]

[Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]

[Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]

[Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]

[Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]

[Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]

[Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

(PMID = 16916294.001).

[ISSN] 1729-0503

[Journal-full-title] African health sciences

[ISO-abbreviation] Afr Health Sci

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Uganda

[Other-IDs] NLM/ PMC1831982

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.

Short, intensive cycles of chemotherapy have resulted in improved survival in BurkittOs lymphoma/leukemia (BL) in adults.

The prognosis of patients with immunodeficiency virus (HIV)-associated BL is considered to be poor, but these patients have seldom been treated with BL-specific protocols.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Leukemia / drug therapy. Lymphoma, AIDS-Related / drug therapy

[MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Aged. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Disease-Free Survival. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Prednisone / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. IFOSFAMIDE .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. LEUCOVORIN .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15996943.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Letter; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; PETHEMA ALL-3-97 protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Controversies in the treatment of Burkitt lymphoma in AIDS.

Increasingly then, the risks of HIV associated cancers become paramount.

Burkitt lymphoma is one of the cancer subtypes highly disproportionately affecting HIV infected patients.

RECENT FINDINGS: Recent conference proceedings appear to corroborate early reports that intensive therapy of HIV-Burkitt lymphoma is feasible and effective.

An optimal approach is not defined due to the small numbers of patients in current trials and the absence of comparison studies.

Moreover, as breakthroughs in the pathogenesis of lymphoma in general and Burkitt lymphoma in particular suggest that HIV infection plays a significant role, the opportunity for targeted therapy based on differences in biology are wholly untapped.

SUMMARY: Advances are being made in HIV-Burkitt lymphoma, but future studies need to incorporate our expanding understanding of biology to improve efficacy and reduce toxicity, preferably by integrating a biologic approach to this curable disease.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]

[Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]

[Cites] Cancer. 2002 Mar 1;94(5):1492-9 [11920506.001]

[Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]

[Cites] Cancer. 2003 Sep 15;98(6):1196-205 [12973843.001]

[Cites] Br J Haematol. 2003 Nov;123(3):475-8 [14617009.001]

[Cites] Cancer. 2004 Feb 15;100(4):667-76 [14770420.001]

[Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Med Clin North Am. 1992 Jan;76(1):253-68 [1727539.001]

[Cites] Am J Clin Pathol. 1995 May;103(5):561-7 [7741100.001]

[Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]

[Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]

[Cites] Semin Oncol. 1998 Apr;25(2 Suppl 4):33-9; discussion 45-8 [9578060.001]

[Cites] Blood. 2004 Nov 15;104(10):3009-20 [15265787.001]

[Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]

[Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]

[Cites] Leukemia. 2008 Sep;22(9):1755-66 [18596745.001]

[Cites] Leukemia. 2009 Apr;23(4):807-10 [18987659.001]

[Cites] Curr Opin Oncol. 2009 Sep;21(5):462-8 [19620863.001]

[Cites] Clin Lymphoma Myeloma. 2009 Aug;9(4):307-10 [19717381.001]

[Cites] Swiss Med Wkly. 2009 Oct 3;139(39-40):564-70 [19838874.001]

[Cites] J Acquir Immune Defic Syndr. 2010 Jan;53(1):124-30 [19730109.001]

[Cites] Br J Haematol. 2010 Jan;148(2):245-55 [19832807.001]

[Cites] Int J Cancer. 2010 Apr 1;126(7):1732-9 [19810101.001]

[Cites] Blood. 2010 Apr 15;115(15):3008-16 [20023215.001]

[Cites] Blood. 2010 Apr 15;115(15):3017-24 [20130244.001]

[Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]

(PMID = 20683266.001).

[ISSN] 1531-703X

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA121947-03S4; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / U01 CA121947-03S4

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Retroviral Agents

[Other-IDs] NLM/ NIHMS237420; NLM/ PMC3415038

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].

Colonoscopy was performed and histological examination of the colon tumor revealed Burkitt's lymphoma (BL).

In the HAART era, the survival of patients with AIDS-related diffuse large cell lymphoma (DLCL) improved dramatically, whereas the survival of similarly treated patients with AIDS-related BL remained poor.

Our case suggests that intensive chemotherapy with hyper-CVAD/MTX-Ara-C combined with HAART may be well tolerated and effective in AIDS-related BL.

[MeSH-major] Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Colonic Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20379116.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CVAD protocol; EPOCH protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lessons from clinical trials in African Burkitt lymphoma.

PURPOSE OF REVIEW: The center of gravity of the AIDS epidemic has moved - in 2007, 67% of all persons living with HIV infection and 72% of all deaths from AIDS occurred in Africa.

The present review focuses on the treatment of an AIDS-defining malignancy, Burkitt lymphoma, since the discovery of the tumor in 1958 to provide a backdrop to the increasing necessity of dealing with AIDS-associated Burkitt lymphoma in Africa.

RECENT FINDINGS: In Africa, it appears that AIDS-associated Burkitt lymphoma is increasing, but although treatment outcome is presently poor, the demonstration that highly active antiretroviral therapy permits the same treatment results to those in AIDS-unassociated Burkitt lymphoma provides hope for the future.

SUMMARY: In the 1960s, the extraordinary response of Burkitt lymphoma to chemotherapy provided considerable encouragement to pioneer oncologists.

Within little more than a decade, the most active drugs, the value of combination chemotherapy, and the need for intrathecal treatment, as well as the risk of tumor lysis syndrome had been demonstrated, providing a platform on which further advances could be made in resource-rich countries.

The impact of the HIV epidemic on the epidemiology and treatment of African Burkitt lymphoma will receive increasing focus in the coming years.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19620863.001).

[ISSN] 1531-703X

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 64

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fatal secondary pulmonary hypertension due to cardiac involvement in AIDS-associated Burkitt's lymphoma.

Primary cardiac lymphomas are rare lesions in children with acquired immunodeficiency syndrome (AIDS).

Most of them are high-grade Burkitt's or Burkitt-like lymphomas.

The clinical profile and operative and pathological findings of a 4-year-old boy with AIDS-associated Burkitt's lymphoma of the heart presenting with acute right heart failure and fatal secondary pulmonary hypertension is reported.

[MeSH-major] Burkitt Lymphoma / complications. Heart Neoplasms / complications. Hypertension, Pulmonary / etiology. Lymphoma, AIDS-Related / complications

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Pulmonary Hypertension.

Genetic Alliance. consumer health - Secondary pulmonary hypertension.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16940688.001).

[ISSN] 0019-5359

[Journal-full-title] Indian journal of medical sciences

[ISO-abbreviation] Indian J Med Sci

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] India

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.

BACKGROUND: Strategies to circumvent or lessen the myelotoxicity associated with combination chemotherapy may improve the overall outcome of the management of patients particularly in resource poor settings.

OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.

CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.

Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.

This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.

[MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16619692.001).

[ISSN] 0012-835X

[Journal-full-title] East African medical journal

[ISO-abbreviation] East Afr Med J

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Kenya

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine

[Number-of-references] 38

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunophenotypic variations of Burkitt lymphoma.

Burkitt lymphoma (BL) exhibits a characteristic immunophenotype that is positive for pan-B-cell antigens and CD10 and expresses clonal surface immunoglobulins (SIgs).

We evaluated 35 BLs and identified atypical immunophenotypes in 4 including SIg light chain negativity in 4, negativity for B-cell antigens in 2, lack of CD10 in 1, and CD4 expression in 1.

The 4 BL cases included 1 girl, 2 men with HIV/AIDS, and a third man with a history of heart transplantation.

Two patients died shortly after diagnosis; the other 2 completed hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone with highly active antiretroviral therapy and achieved complete remission.

If the immunophenotype is interpreted in isolation, the diagnosis could be missed.

Recognizing the variability of immunophenotype is essential for establishing an accurate diagnosis of BL.

[MeSH-major] Burkitt Lymphoma / immunology. Immunophenotyping. Lymphoma, AIDS-Related / immunology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20551277.001).

[ISSN] 1943-7722

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] RB and cell cycle progression.

The Rb protein is a tumor suppressor, which plays a pivotal role in the negative control of the cell cycle and in tumor progression.

It has been shown that Rb protein (pRb) is responsible for a major G1 checkpoint, blocking S-phase entry and cell growth.

Loss of pRb functions may induce cell cycle deregulation and so lead to a malignant phenotype.

Functional inactivation of pRb by viral oncoprotein binding is also shown in many neoplasias such as cervical cancer, mesothelioma and AIDS-related Burkitt's lymphoma.

[MeSH-major] Cell Cycle / genetics. Retinoblastoma Protein / genetics

[MeSH-minor] Cell Division / genetics. Chromosome Mapping. Chromosomes, Human, Pair 13. Genes, Tumor Suppressor. Humans. Transcription, Genetic. Tumor Suppressor Proteins / genetics

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16936740.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins

[Number-of-references] 86

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Burkitt's lymphoma of the caecum in a patient with AIDS: clinical case and review of the literature].

[Transliterated title] Linfoma di Burkitt del cieco in paziente con AIDS conclamato: caso clinico e revisione della letteratura.

The incidence of primary colic lymphoma, above all in the non-Hodgkin variant, is clearly higher in the HIV positive population, especially in subjects with AIDS.

The authors present the case of a 51-year-old patient with AIDS undergoing antiviral therapy; he was suffering from abdominal pain and presented a palpable mass in the right iliac fossa; diagnosis was caecal non-Hodgkin lymphoma (NHL); radical right hemicolectomy was carried out with definitive histological diagnosis of Burkitt-type small cell NHL.

Nevertheless such cases are comparatively frequent in patients with HIV virus, especially in the active phase and clinically proven to be due to immunodeficient syndrome.

Of cardinal importance is the differential diagnosis between primary and secondary forms because of the different treatment and prognosis.

Frequently such forms are observed in patients with AIDS, at advanced stages and with differentiated and hence more aggressive histotypes, also because they are present in organisms weakened by the underlying disease and by immunodeficiency.

Primary NHLs of the colon are relatively frequent and aggressive in patients with AIDS; early diagnosis and treatment are therefore of fundamental importance to improve the oncological outcome for these patients.

[MeSH-major] Burkitt Lymphoma. Cecal Neoplasms. Immunocompromised Host. Lymphoma, AIDS-Related

[MeSH-minor] Abdominal Pain / etiology. Diagnosis, Differential. HIV-1 / isolation & purification. Humans. Male. Middle Aged. Treatment Outcome

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19365324.001).

[ISSN] 0026-4733

[Journal-full-title] Minerva chirurgica

[ISO-abbreviation] Minerva Chir

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] Italy

[Number-of-references] 22

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.

The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen.

In a multi-variable Cox regression analysis, treatment according to the GMALL protocol was significantly associated with prolonged survival with a relative hazard rate of 0.13 (95% CI 0.03 - 0.63, P = 0.01).

In conclusion, the short and intensive GMALL protocol for B-ALL/NHL is feasible in patients with AIDS-BL/BLL.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DAUNORUBICIN .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. MERCAPTOPURINE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17065000.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] England

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.

PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.

PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).

RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.

Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Steroids.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. LEUCOVORIN .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Clin Oncol. 2005 Nov 20;23(33):8538-40; author reply 8540-1 [16293885.001]

[CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8132-3; author reply 8133-4 [16258119.001]

(PMID = 15883411.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.

Morphologic features of Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) overlap.

We tested a panel of 8 germinal center (GC) and activated B-cell (ABC) markers for their ability to separate BL and DLBCL.

We diagnosed 16 BL and 39 DLBCL cases from 21 patients with AIDS and 34 without AIDS based on traditional morphologic criteria, Ki-67 proliferative index, and c-myc rearrangement (fluorescence in situ hybridization).

Hierarchical clustering yielded 2 major clusters significantly associated with morphologic diagnosis (P < .001).

This revealed a high-GC/low-ABC group and a low-GC/high-ABC group that were associated significantly with morphologic diagnosis (P < .001).

[MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / pathology. Germinal Center / immunology. Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphocyte Activation. Male. Middle Aged. Retrospective Studies

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16203284.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Improving outcomes for patients with Burkitt lymphoma and HIV.

Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy that occurs with increased frequency among patients infected with HIV.

However, the advent of highly active antiretroviral therapy (HAART) and the mounting evidence that less intensive lymphoma regimens are ineffective in BL have led investigators to treat HIV-positive patients with the same chemotherapy now established as the standard of care for immunocompetent patients.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma. Lymphoma, AIDS-Related / physiopathology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Pneumocystosis and HIV .

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18290753.001).

[ISSN] 1557-7449

[Journal-full-title] AIDS patient care and STDs

[ISO-abbreviation] AIDS Patient Care STDS

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

[Number-of-references] 46

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.

Burkitt lymphoma is the most common AIDS-related lymphoma (ARL) in childhood.

We present a case of advanced stage Burkitt lymphoma in an 8-year-old female with acquired immunodeficiency syndrome (AIDS), who was successfully treated with a 3 month course of modified CHOP-R (cyclophosphamide, daunorubicin, vincristine, prednisone, and rituximab) and HAART therapy.

The combination of rituximab and chemotherapy with HAART therapy may be well-tolerated and effective in HIV/AIDS patients with Burkitt lymphoma.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

(PMID = 17278123.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fatal adenovirus pneumonia in a person with AIDS and Burkitt lymphoma: a case report and review of the literature.

Although adenoviruses are a recognized cause of serious pulmonary and disseminated disease among stem cell transplant recipients, their importance in other immunocompromised patient populations is less clearly documented.

We present a case of a person with AIDS who was receiving chemotherapy for Burkitt lymphoma in whom fatal adenovirus pneumonia and adenoviremia developed, and we review the published literature on adenovirus infection in the setting of HIV disease.

[MeSH-major] Acquired Immunodeficiency Syndrome. Adenoviridae Infections. Burkitt Lymphoma / drug therapy. HIV-1. Lymphoma, AIDS-Related / drug therapy. Pneumonia, Viral

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18472442.001).

[ISSN] 1053-0894

[Journal-full-title] The AIDS reader

[ISO-abbreviation] AIDS Read

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antiviral Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] EBV and HIV-Related Lymphoma.

HIV-associated lymphoproliferative disorders represent a heterogeneous group of diseases, arising in the presence of HIV-associated immunodeficiency.

The overall prevalence of HIV-associated lymphoma is significantly higher compared to that of the general population and it continues to be relevant even after the wide availability of highly active antiretroviral therapy (HAART) (1).

It has been largely implicated in the development of B-cell lymphoproliferative disorders as Burkitt lymphoma (BL), Hodgkin disease (HD), systemic non Hodgkin lymphoma (NHL), primary central nervous system lymphoma (PCNSL), nasopharyngeal carcinoma (NC).

Virus-associated lymphomas are becoming of significant concern for the mortality of long-lived HIV immunocompromised patients, and therefore, research of advanced strategies for AIDS-related lymphomas is an important field in cancer chemotherapy.

Detailed understanding of the EBV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy The linkage of HIV-related lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and possibly therapeutic implications which are reviewed herein.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Oncol. 1999 Jun;26(3):346-56 [10375091.001]

[Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]

[Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]

[Cites] J Exp Med. 2001 Dec 17;194(12):1731-41 [11748275.001]

[Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]

[Cites] Nat Med. 2002 Apr;8(4):319-23 [11927927.001]

[Cites] AIDS. 2002 May 24;16(8):1195-6 [12004285.001]

[Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]

[Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15572-7 [12434018.001]

[Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]

[Cites] Cancer Res. 2003 Jun 1;63(11):2982-9 [12782607.001]

[Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]

[Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]

[Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]

[Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]

[Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]

[Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]

[Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]

[Cites] Am J Hematol. 2008 Oct;83(10):763-4 [18756546.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] J Clin Oncol. 1993 Sep;11(9):1674-81 [8394878.001]

[Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]

[Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]

[Cites] J Exp Med. 1991 Jan 1;173(1):147-58 [1845872.001]

[Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]

[Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]

[Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]

[Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]

[Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]

[Cites] J Virol. 1996 Feb;70(2):1143-53 [8551575.001]

[Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]

[Cites] Curr Opin Oncol. 1996 Sep;8(5):373-6 [9026061.001]

[Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]

[Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]

[Cites] Neurology. 2000 Feb 22;54(4):993-7 [10691003.001]

[Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]

[Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]

[Cites] J Clin Invest. 1997 Apr 1;99(7):1525-33 [9119996.001]

[Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]

[Cites] J Clin Pathol. 1997 Nov;50(11):911-8 [9462239.001]

[Cites] Am J Pathol. 1998 Mar;152(3):623-30 [9502401.001]

[Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]

[Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]

[Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]

[Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]

[Cites] AIDS. 2002 Oct 18;16(15):2001-11 [12370498.001]

[Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]

[Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]

[Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]

[Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]

[Cites] Am J Hematol. 2003 Jul;73(3):143-8 [12827649.001]

[Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]

[Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]

[Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]

[Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]

[Cites] Neurology. 1997 Mar;48(3):687-94 [9065549.001]

[Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]

[Cites] Presse Med. 2004 Dec 4;33(21):1487-92 [15637794.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]

[Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]

[Cites] Hematol Oncol. 2005 Jun;23(2):61-7 [16216037.001]

[Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]

[Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]

[Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]

[Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]

[Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]

[Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]

[Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]

[Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]

[Cites] Blood Rev. 2008 Sep;22(5):261-81 [18456377.001]

[Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]

[Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]

[Cites] AIDS. 1997 Oct;11(12):1522-3 [9342077.001]

[Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]

[Cites] J Natl Cancer Inst. 1998 Mar 4;90(5):364-9 [9498486.001]

[Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]

[Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]

[Cites] Immunity. 1998 Sep;9(3):405-11 [9768760.001]

[Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]

[Cites] AIDS. 2001 Nov 9;15(16):2119-27 [11684931.001]

[Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]

[Cites] Dermatology. 2004;208(3):287-90 [15118393.001]

[Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]

[Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]

[Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]

[Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]

[Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]

[Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]

[Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]

[Cites] Crit Rev Oncog. 1998;9(3-4):199-208 [10201628.001]

(PMID = 21416008.001).

[ISSN] 2035-3006

[Journal-full-title] Mediterranean journal of hematology and infectious diseases

[ISO-abbreviation] Mediterr J Hematol Infect Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

[Other-IDs] NLM/ PMC3033170

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada.

OBJECTIVE: To examine the influence of the AIDS epidemic on the incidence of Kaposi sarcoma (KS) and non-Hodgkin lymphoma (NHL) in Ontario.

AIDS cases were extracted from Ontario Ministry of Health and Long-Term Care reports.

CONCLUSIONS: The AIDS epidemic, the introduction of antiretroviral therapies, and the decrease in HIV infection rates explain the rise and decline of KS incidence in Ontario.

NHL incidence trends are more complex, although the AIDS epidemic explains the trends observed in younger men (in whom AIDS is more common), and for the AIDS-related subtypes.

[MeSH-major] Acquired Immunodeficiency Syndrome / epidemiology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Population Surveillance. Sarcoma, Kaposi / epidemiology

[MeSH-minor] Adult. Burkitt Lymphoma / epidemiology. Humans. Incidence. Logistic Models. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large-Cell, Immunoblastic / epidemiology. Male. Ontario / epidemiology. Registries / statistics & numerical data. Retrospective Studies

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18618279.001).

[ISSN] 1573-7225

[Journal-full-title] Cancer causes & control : CCC

[ISO-abbreviation] Cancer Causes Control

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.

BACKGROUND: It has been recognized that cure is possible for human immunodeficiency virus (HIV)-infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy is used.

[MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (Copyright) 2008 American Cancer Society.

(PMID = 18457327.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary meningeal Burkitt-type lymphoma presenting as the first clinical manifestation of acquired immunodeficiency syndrome.

The purpose of this study is to report a rare case of primary meningeal high grade Burkitt-type lymphoma presenting as the first clinical manifestation of acquired immunodeficiency syndrome.

Some hours after the surgery, the patient developed hemispheric cerebral edema and intracranial hypertension syndrome.

Screening blood tests diagnosed human immunodeficiency virus infection.

Pathological studies diagnosed Burkitt-type lymphoma.

[MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16917629.001).

[ISSN] 0004-282X

[Journal-full-title] Arquivos de neuro-psiquiatria

[ISO-abbreviation] Arq Neuropsiquiatr

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005.

Burkitt lymphoma (BL) is a unique B-cell non-Hodgkin lymphoma with 3 established clinical-epidemiological variants: endemic, sporadic and AIDS-related BL.

Therefore, we examined population-based BL incidence patterns in the United States to determine age-related risk.

The tri/bimodal incidence pattern was present in sensitivity analyses excluding registries with many HIV/AIDS cases and in period-specific, cohort-specific analyses.

[MeSH-major] Burkitt Lymphoma / epidemiology

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2009 UICC.

[Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]

[Cites] Biometrics. 1995 Sep;51(3):874-87 [7548706.001]

[Cites] Am J Epidemiol. 1996 Jan 1;143(1):85-91 [8533751.001]

[Cites] Blood. 1999 Feb 1;93(3):1124 [10025990.001]

[Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]

[Cites] Cancer. 1957 Sep-Oct;10(5):1045-54 [13472655.001]

[Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]

[Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]

[Cites] Ann Intern Med. 1969 Apr;70(4):817-32 [4306129.001]

[Cites] Br J Prev Soc Med. 1971 Nov;25(4):242-4 [5160433.001]

[Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]

[Cites] Eur J Cancer. 1972 Jun;8(3):305-8 [4677829.001]

[Cites] N Engl J Med. 1981 Sep 24;305(13):735-45 [7022215.001]

[Cites] Lancet. 1982 Sep 18;2(8299):631-3 [6125777.001]

[Cites] Biometrics. 1983 Jun;39(2):311-24 [6626659.001]

[Cites] Stat Med. 1987 Jun;6(4):449-67 [3629047.001]

[Cites] Stat Med. 1987 Jun;6(4):469-81 [3629048.001]

[Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]

[Cites] Br J Cancer. 1963 Mar;17:50-5 [14001942.001]

[Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]

[Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]

[Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14 [19066264.001]

[Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2256-61 [19622723.001]

[Cites] MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92 [16741494.001]

[Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] MMWR Suppl. 1987 Dec 25;36(7):1S-20S [2826984.001]

[Cites] Annu Rev Public Health. 1991;12:425-57 [2049144.001]

[Cites] Am J Epidemiol. 1987 Oct;126(4):578-86 [3631049.001]

(PMID = 19810101.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z01 CP010176-07; United States / Intramural NIH HHS / / ZIA CP010176-08

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Other-IDs] NLM/ NIHMS146203; NLM/ PMC2818154

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.

Human immunodeficiency virus-infected patients are at an increased risk for developing both Hodgkin and non-Hodgkin lymphoma when compared with the general population.

With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-related lymphoma (ARL) is now the second most common cancer associated with human immunodeficiency virus after Kaposi sarcoma.

Apart from the contribution of HAART, this improvement in prognosis can also be attributed to new initiatives in treatment of these patients, such as the use of effective infusional regimens, the feasibility of high-dose therapy with peripheral stem cell rescue for relapsed or refractory disease, and better supportive care.

Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology

[MeSH-minor] AIDS-Related Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16020424.001).

[ISSN] 0007-9235

[Journal-full-title] CA: a cancer journal for clinicians

[ISO-abbreviation] CA Cancer J Clin

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 52

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Spinal compression due to Burkitt lymphoma in a newly diagnosed HIV-infected child.

We describe a newly diagnosed HIV-infected child, without prior history of AIDS-defining disease, who presented with Burkitt lymphoma-related cauda equina syndrome that rapidly progressed to a flaccid paraplegia.

Diagnosis was confirmed on biopsy and magnetic resonance imaging of the spine showed multiple epidural masses with involvement of several vertebral bodies, cord edema and compression of the cord and cauda equina.

The patient is the first reported case of Burkitt lymphoma-related spinal cord compression as an initial AIDS-defining illness, in a 10-year-old child.

The outcome of the case highlights the importance of early diagnosis and prompt treatment of this aggressive tumor to avoid permanent neurologic deficits.

[MeSH-major] Burkitt Lymphoma / complications. HIV Infections / complications. Polyradiculopathy / etiology. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / complications

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19346875.001).

[ISSN] 1536-3678

[Journal-full-title] Journal of pediatric hematology/oncology

[ISO-abbreviation] J. Pediatr. Hematol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Morphological spectrum of AIDS-related plasmablastic lymphomas.

We have had a recent spurt in cases of AIDS-related lymphoma (ARL) at our centre.

Most of these cases are aggressive mature B cell lymphomas, mainly plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL).

Diagnosis was based on morphology, immunohistochemistry, proliferation index, HIV positive status and its preference to extranodal sites (mostly mucosa based).

We classified PBL into three morphological subtypes (immunoblastic - 25, Burkitt's - 7, plasmacytic - 2).

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunoglobulin Light Chains / analysis. Leukemia, Plasma Cell / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Syndecan-1 / analysis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18417882.001).

[ISSN] 0377-4929

[Journal-full-title] Indian journal of pathology & microbiology

[ISO-abbreviation] Indian J Pathol Microbiol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Light Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; EC 3.1.3.48 / Antigens, CD45

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.

OBJECTIVES: To assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART).

METHODS: We analyzed the Grupo de Estudio del SIDA register of systemic ARL, which started in Jan 1994, to collect cases diagnosed at 15 institutions prospectively and with active follow-up every 6 months.

Histologic subtypes were diffuse large B-cell lymphoma (DLCL; n = 153 [72.9%]), Burkitt and atypical Burkitt/Burkitt-like lymphoma (BL; n = 40 [19.0%]), T-cell lymphoma (TC; n = 8 [3.8%]), and miscellaneous (n = 9 [4.3%]).

Factors independently associated with CR were histologic subtype and International Prognostic Index (IPI) score.

Factors independently associated with improved overall length of survival (OS) were CR, low IPI score, and histologic subtype.

The single factor independently associated with disease-free survival was Ann Arbor stage.

CONCLUSIONS: In patients with ARL treated with HAART, CR was associated exclusively with tumor-related factors.

OS was independently associated with CR, IPI score, and the histologic subtype.

[MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Remission Induction. Statistics as Topic. Survival Analysis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17117144.001).

[ISSN] 1525-4135

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-HIV Agents

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas.

In some subtypes of non-Hodgkin's lymphomas, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density.

We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the AIDS-related diffuse large B-cell (DLBCL) and Burkitt lymphomas (BL).

Reduced VEGF protein expression in primary HIV-1 positive BL and DLBCL, compared to the negative cases, supported the findings of promoter downregulation from the cell lines.

Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the AIDS-associated tumors will open a window for future explorable pathways in the management of angiogenic phenotypes in the AIDS-associated non-Hodgkin's lymphomas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Med. 1996 Dec;2(12):1371-5 [8946838.001]

[Cites] Oncogene. 2000 Jan 20;19(3):373-9 [10656684.001]

[Cites] Oncogene. 1996 Jan 18;12(2):289-97 [8570206.001]

[Cites] Nature. 1995 Jul 6;376(6535):66-70 [7596436.001]

[Cites] Leuk Lymphoma. 2007 Oct;48(10):2014-21 [17917969.001]

[Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]

[Cites] Exp Cell Res. 2007 May 1;313(8):1561-74 [17382929.001]

[Cites] Am J Pathol. 2007 Apr;170(4):1362-9 [17392174.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4647-52 [17360578.001]

[Cites] Biochem Biophys Res Commun. 2007 Apr 13;355(3):693-9 [17320821.001]

[Cites] Nat Struct Mol Biol. 2007 Mar;14(3):249-50 [17293873.001]

[Cites] J Cell Biochem. 2007 Feb 15;100(3):727-37 [17115409.001]

[Cites] Curr Med Chem. 2006;13(16):1845-57 [16842197.001]

[Cites] FEBS J. 2005 Nov;272(22):5723-41 [16279938.001]

[Cites] Folia Histochem Cytobiol. 2004;42(4):241-3 [15704651.001]

[Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]

[Cites] Circulation. 1997 Dec 2;96(11):4083-94 [9403634.001]

[Cites] J Biol Chem. 1998 Nov 20;273(47):31119-24 [9813014.001]

[Cites] Science. 1998 Dec 4;282(5395):1837-9 [9874635.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6 [9520456.001]

[Cites] J Clin Pathol. 1997 Jun;50(6):481-4 [9378813.001]

[Cites] Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):233-5 [7542074.001]

[Cites] Cancer Res. 1995 Sep 15;55(18):3964-8 [7664263.001]

[Cites] Nature. 1994 Oct 20;371(6499):674-80 [7935812.001]

[Cites] Arch Orthop Trauma Surg. 2003 Nov;123(9):475-80 [12750926.001]

[Cites] Angiogenesis. 2002;5(3):141-51 [12831055.001]

[Cites] Cell Prolif. 2003 Jun;36(3):131-49 [12814430.001]

[Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]

[Cites] Curr Drug Targets Infect Disord. 2003 Jun;3(2):115-28 [12769789.001]

[Cites] J Rheumatol. 2003 Feb;30(2):260-8 [12563678.001]

[Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]

[Cites] Hum Pathol. 2002 Jul;33(7):723-31 [12196924.001]

[Cites] Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44 [11965229.001]

[Cites] Clin Microbiol Rev. 2002 Apr;15(2):310-26 [11932235.001]

[Cites] Am J Clin Pathol. 2001 Dec;116(6):838-45 [11764072.001]

[Cites] Biochem J. 2001 Feb 1;353(Pt 3):569-78 [11171054.001]

[Cites] Cancer Res. 2001 Jan 15;61(2):462-8 [11212232.001]

[Cites] Curr Opin Oncol. 2000 Sep;12(5):445-9 [10975552.001]

[Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):267-71 [10873597.001]

[Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]

[Cites] Am J Pathol. 1996 Apr;148(4):1065-74 [8644848.001]

(PMID = 19669199.001).

[ISSN] 1868-9256

[Journal-full-title] Journal of hematopathology

[ISO-abbreviation] J Hematop

[Language] eng

[Publication-type] Journal Article

[Publication-country] Germany

[Other-IDs] NLM/ PMC2712328

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphomas: from pathogenesis to pathology.

Human immunodeficiency virus (HIV)-associated lymphomas include:.

The vast majority of these lymphomas are high-grade B-cell lymphomas: Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) with centroblastic (CB) features and DLBCL with immunoblastic (IBL) features;.

(2) unusual lymphomas occurring more specifically in HIV-positive patients and include two rare entities, namely 'primary effusion lymphoma' (PEL) and 'plasmablastic lymphoma' of the oral cavity.

The pathological heterogeneity of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas (AIDS-NHL) reflects the heterogeneity of their associated molecular lesions.

In AIDS-BL, the molecular lesions involve activation of cMYC, inactivation of P53, and infection with Epstein-Barr virus (EBV).

AIDS-IBL infected with EBV are characterised by frequent expression of latent membrane protein 1--an EBV oncoprotein.

The biological heterogeneity of AIDS-NHL is highlighted by their histogenetic differences.

Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV8)-associated lymphomas, which often develop in persons with advanced AIDS, present predominantly as PEL.

The KSHV/HHV8-associated solid lymphomas are (1) unusual lymphomas that occur more specifically in HIV-positive patients;.

(2) extracavitary and arise in nodal and/or extranodal sites; and (3) histologically, they usually display a PEL-like morphology and plasma cell-related phenotype.

[MeSH-major] HIV-1. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin. Sarcoma, Kaposi

[MeSH-minor] Diagnosis, Differential. Herpesvirus 8, Human. Humans

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16115121.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Number-of-references] 53

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Advances in the management of HIV-related non-Hodgkin lymphoma.

PURPOSE OF REVIEW: Human immunodeficiency virus infection is associated with an increased risk of non-Hodgkin lymphoma.

Even with a decrease in AIDS-defining illnesses after the advent of highly active antiretroviral therapy, HIV-associated non-Hodgkin lymphoma remains an important problem.

RECENT FINDINGS: Low CD4+ T-lymphocyte count, disease stage, performance status, serum lactate dehydrogenase, and number of extranodal sites of disease are all important prognostic factors for HIV-non-Hodgkin lymphoma.

Recent studies have examined the role of infusional chemotherapy, as well as immunotherapy, in the treatment of aggressive HIV-non-Hodgkin lymphoma, and autologous stem cell transplantation for relapsed or refractory HIV-non-Hodgkin lymphoma.

New developments in the association of viral infection and pathogenesis of certain subtypes of HIV-non-Hodgkin lymphoma have also recently been reported.

SUMMARY: Outcomes of HIV-non-Hodgkin lymphoma are improving with the routine use of highly active antiretroviral therapy and combination chemotherapy.

For aggressive HIV-non-Hodgkin lymphoma, infusional chemotherapy regimens are well tolerated and lead to complete response in about 50-75% of cases and a 2-3 years overall survival of 40-60%.

HIV-associated Burkitt lymphoma should be treated with an intensive regimen rather than standard cyclophosphamide, doxorubicin, vincristine, prednisone-like chemotherapy.

Autologous stem cell transplantation should be considered for selected patients with relapsed or refractory HIV-non-Hodgkin lymphoma.

[MeSH-major] Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy. Lymphoma, Non-Hodgkin / therapy. Stem Cell Transplantation

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16894290.001).

[ISSN] 1040-8746

[Journal-full-title] Current opinion in oncology

[ISO-abbreviation] Curr Opin Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Retroviral Agents

[Number-of-references] 65

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.

BACKGROUND: Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS.

With the advent of highly active antiretroviral therapy (HAART), the incidence and mortality of AIDS-related opportunistic infections and Kaposi's sarcoma has fallen dramatically, this trend is not observed so clearly for NHL.

Our objective was to review the clinical spectrum of patients with AIDS-associated NHL and to analyze the impact of HAART on survival at an oncological tertiary center.

MATERIAL AND METHODS: We reviewed all medical records and histopathologic tissue of patients with HIV-associated NHL seen from January 1990 to September 2007 at the Instituto Nacional de Cancerologia in Mexico City.

Survival or follow-up time was calculated from date of diagnosis to death, or to the date on which the patient was last seen.

RESULTS: Eighty seven HIV-positive patients were diagnosed with NHL (diffuse large B-cell lymphoma n=69; Burkitt-like n=8; pleomorphic large cell n=7; low-grade n=2, and angiocentric n=1).

Overall, 38 patients (43.7%) achieved complete response to NHL therapy, including only 14.3% patients in the non-HAART compared with 57.6% in the HAART group (p < or = 0.0001).

Two patients (7.1%) in the non-HAART were alive compared with 37 (63.8%) in the HAART group (p < or = 0.0001).

[MeSH-major] Cancer Care Facilities / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

[MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Mexico / epidemiology. Middle Aged. Retrospective Studies. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19227434.001).

[ISSN] 0034-8376

[Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición

[ISO-abbreviation] Rev. Invest. Clin.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Mexico

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Non Hodgkin's lymphoma with cutaneous involvement in AIDS patients: report of five cases and review of the literature.

Cutaneous B cell lymphoma (CBCL) is a lymphoproliferative disorder of neoplastic B cell of the skin with a wide range of clinical manifestations.

Skin is one of the common sites for extra-nodal lymphomas in patients with AIDS and B cell type is less common than T cell type.

Only recently, the existence of B cell lymphomas presenting clinically in the skin without evidence of extra-cutaneous involvement has been accepted as primary CBCL.

Here, we are presenting 5 patients with cutaneous involvement in the setting of HIV/AIDS disease.

Two of them were primary cutaneous non-Hodgkin lymphomas.

All were CBCL; 3 were immunoblastic, 1 was plasmablastic, and the other was a Burkitt lymphoma.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Skin Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Skin Cancer.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20428660.001).

[ISSN] 1678-4391

[Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

[ISO-abbreviation] Braz J Infect Dis

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.

BACKGROUND: AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART).

We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma.

RESULTS: In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27-2.20]) (P < .001]).

This association differed markedly between lymphoma subtypes.

Although the association was more pronounced for Burkitt-type lymphoma (HR, 3.45 [95% CI, 1.52-7.85]) (P = .003), there was no association between cumulative HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39-2.57]) (P = .997).

Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4 T cell count as well as age per 10-year increment.

CONCLUSIONS: Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving HAART.

The influence of cumulative HIV viremia may differ between lymphoma subtypes.

[MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Viremia / complications

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Infect Dis. 2009 Jul 1;200(1):8-10 [19476436.001]

(PMID = 19476437.001).

[ISSN] 0022-1899

[Journal-full-title] The Journal of infectious diseases

[ISO-abbreviation] J. Infect. Dis.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Investigator] Kuehne A; Arastéh K; Kowol S; Bergmann F; Warnke M; Brockmeyer N; Mühlbächer N; Rockstroh J; Wasmuth J; Oette M; Blondin C; Esser S; Schenk-Westkamp P; Plettenberg A; Lorenzen T; Walther I; Adam A; Weitner L; Schewe K; Goey H; Fenske S; Buhk T; Gellerman H; Wassmuss K; Stoll M; Gerschmann S; Horst H; Fätkenheuer G; Kümmerle T; Gillor D; Bogner J; Sonntag B; Salzberger B; Fritzsche C

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.

BACKGROUND: The pathologic heterogeneity of AIDS related lymphomas (ARL) reflects several pathogenic mechanisms: chronic antigenic stimulation, Epstein-Barr virus (EBV) infection, and genomic abnormalities.

Genetic abnormalities, known to play a major role in lymphomas of non-immunocompromised patients, are not well characterized in ARL.

Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.

CONCLUSION: This CGH study allowed the identification of non-random chromosomal alterations in ARL.

The results suggested an inverse relationship between EBV infection (latency II/III), associated with deep acquired immune suppression, and the number of chromosomal alterations which may be explained by a direct role of viral proteins in lymphomagenesis by activation of signalling pathways without needing several genomic alterations.

[MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics

[MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17117014.001).

[ISSN] 0269-9370

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Viral

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] T-helper 1 versus T-helper 2 lymphocyte immunodysregulation is the central factor in genesis of Burkitt lymphoma: hypothesis.

BACKGROUND: The HIV epidemic has challenged our previous understanding of endemic Burkitt's lymphoma.

Despite the strong association of Burkitt's lymphoma and HIV infection in the Developed world, and against previous postulations that the cancer is due to immunosupression among African children, the HIV epidemic in the Malaria belt has not been associated with a corresponding increase in incidence of childhood Burkitt's lymphoma.

Even outside the context of HIV infection, there is substantial evidence for a strong but skewed immune response towards a TH2 response in genesis of Burkitt lymphoma.

PRESENTATION OF THE HYPOTHESIS: Rather than a global and/or profound immunosupression, the final common pathway in genesis of Burkitt's lymphoma is the dysregulation of the immune response towards a TH2 response dominated by B-lymphocytes, and the concomitant suppression of the TH1 cell-mediated immune surveillance, driven by various viral/parasitic/bacterial infections.

TESTING THE HYPOTHESIS: Case control studies comparing TH2 and TH1 immune responses in Burkitt lymphoma of different etiological types (sporadic, HIV-related, endemic and post-transplant) to demonstrate significant dominance of TH2 immune response in presence of poor CMI response as a common factor.

Immunological profiling to evaluate differences between immune states that are associated (such as recurrent Malaria infection) and those that are not associated (such as severe protein-energy malnutrition) with Burkitt lymphoma.

Prospective cohorts profiling chronology of immunological events leading to Burkitt lymphoma in children with EBV infection.

IMPLICATIONS OF THE HYPOTHESIS: The dysregulation of the immune response may be the missing link in our understanding of Burkitt lymphomagenesis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]

[Cites] P N G Med J. 1986 Mar;29(1):41-3 [3019040.001]

[Cites] Proc R Soc Med. 1971 Sep;64(9):909-10 [4329792.001]

[Cites] Clin Exp Immunol. 1984 May;56(2):371-6 [6329564.001]

[Cites] Prog Food Nutr Sci. 1984;8(3-4):193-228 [6396715.001]

[Cites] Fed Proc. 1980 Nov;39(13):3098-104 [6968692.001]

[Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]

[Cites] Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5 [7574850.001]

[Cites] Immunol Rev. 1994 Aug;140:73-92 [7821929.001]

[Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]

[Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]

[Cites] AIDS. 1996 Jun;10(6):643-7 [8780819.001]

[Cites] Am J Pathol. 1976 Sep;84(3):599-614 [8988.001]

[Cites] Ann Oncol. 1997 Oct;8(10):987-94 [9402172.001]

[Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]

[Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]

[Cites] Cent Afr J Med. 1998 Oct;44(10):242-5 [10101432.001]

[Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]

[Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]

[Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]

[Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]

[Cites] J Gen Virol. 2001 Dec;82(Pt 12):3051-5 [11714983.001]

[Cites] J Natl Cancer Inst. 1976 Mar;56(3):479-83 [1255780.001]

[Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]

[Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]

[Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]

[Cites] Int J Immunopharmacol. 1992 Apr;14(3):361-6 [1618590.001]

[Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]

[Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]

[Cites] Transplantation. 2006 Oct 27;82(8):1013-23 [17060848.001]

[Cites] Eur J Cancer Prev. 2007 Feb;16(1):55-61 [17220705.001]

[Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]

[Cites] Int J Cancer. 1990 Apr 15;45(4):650-3 [2323841.001]

[Cites] Paediatr Perinat Epidemiol. 1990 Jul;4(3):303-24 [2374749.001]

[Cites] Am J Epidemiol. 1989 Apr;129(4):740-52 [2923122.001]

[Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]

(PMID = 17509139.001).

[ISSN] 1750-9378

[Journal-full-title] Infectious agents and cancer

[ISO-abbreviation] Infect. Agents Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC1884132

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.

Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals.

A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005.

The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies).

Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%).

Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users.

Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%).

Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%.

Kaposi's sarcoma-associated herpesvirus infection was rare (4%) among all cases.

These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16697236.001).

[ISSN] 1286-4579

[Journal-full-title] Microbes and infection

[ISO-abbreviation] Microbes Infect.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV infection and lymphoma.

The incidence of lymphoma in patients with HIV infection greatly exceeds that of the general population.

The increased risk for lymphoma appears related to multiple factors, including the transforming properties of the retrovirus itself, the immunosuppression and cytokine dysregulation that results from the disease, and, most importantly, opportunistic infections with other lymphotrophic herpes viruses such as Epstein-Barr virus and human herpesvirus 8.

However, following the introduction of highly active antiretroviral therapy, the risk for developing lymphoma in the context of HIV infection has decreased and the clinical outcome has improved.

[MeSH-major] Lymphoma, AIDS-Related / pathology

[MeSH-minor] Burkitt Lymphoma / immunology. Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Hodgkin Disease / immunology. Hodgkin Disease / pathology. Hodgkin Disease / virology. Humans. Immunocompetence. Immunocompromised Host. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] AIDS. 2002 Sep 6;16(13):1803-7 [12218393.001]

[Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]

[Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]

[Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]

[Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]

[Cites] Am J Otolaryngol. 1999 Jan-Feb;20(1):56-8 [9950115.001]

[Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]

[Cites] Int J Dermatol. 1999 Feb;38(2):111-8 [10192159.001]

[Cites] Am J Surg Pathol. 1999 May;23(5):519-22 [10328082.001]

[Cites] Am J Surg Pathol. 1999 May;23(5):560-6 [10328088.001]

[Cites] Blood. 1999 Jul 1;94(1):275-82 [10381523.001]

[Cites] J Clin Pathol. 1999 Apr;52(4):313-6 [10474529.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]

[Cites] AIDS Res Hum Retroviruses. 2004 Feb;20(2):129-33 [15018699.001]

[Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]

[Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]

[Cites] Dermatology. 2004;208(3):287-90 [15118393.001]

[Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1020-7 [15247554.001]

[Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]

[Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]

[Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]

[Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]

[Cites] Cancer. 1988 Jun 1;61(11):2325-37 [3365660.001]

[Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]

[Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]

[Cites] J Clin Oncol. 1992 Mar;10(3):383-9 [1311023.001]

[Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]

[Cites] Am J Epidemiol. 1994 Feb 15;139(4):362-8 [8109570.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] Curr Opin Oncol. 1994 Sep;6(5):492-6 [7827152.001]

[Cites] Am J Surg Pathol. 1995 Mar;19(3):357-63 [7872434.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] N Engl J Med. 1996 Jul 4;335(1):61-2 [8637555.001]

[Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]

[Cites] Histopathology. 1996 Feb;28(2):129-34 [8834520.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15;13(5):467-8 [8970478.001]

[Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):722-7 [10534634.001]

[Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]

[Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]

[Cites] N Engl J Med. 2000 Mar 30;342(13):930-6 [10738051.001]

[Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]

[Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]

[Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]

[Cites] Arch Dermatol. 2005 Oct;141(10):1321-2 [16230579.001]

[Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]

[Cites] J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):558-64 [16284532.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]

[Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]

[Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]

[Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]

[Cites] Mod Pathol. 2006 Mar;19(3):438-46 [16444194.001]

[Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]

[Cites] Am J Surg Pathol. 2003 Mar;27(3):293-302 [12604885.001]

[Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]

[Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]

[Cites] Hum Pathol. 2003 Sep;34(9):950-4 [14562294.001]

[Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]

[Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]

[Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]

[Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):371-6 [11317081.001]

[Cites] Arch Pathol Lab Med. 2001 Sep;125(9):1246-8 [11520284.001]

[Cites] AIDS. 2001 Sep 28;15(14):1913-5 [11579268.001]

[Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]

[Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]

[Cites] Cancer. 2002 Mar 1;94(5):1500-6 [11920507.001]

[Cites] Arch Pathol Lab Med. 2002 Jun;126(6):738-41 [12033970.001]

[Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]

(PMID = 18042692.001).

[ISSN] 1472-4146

[Journal-full-title] Journal of clinical pathology

[ISO-abbreviation] J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 80

[Other-IDs] NLM/ PMC2095580

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.

HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.

Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.

To aid in case classification and identify key pathogenetic events in ARL, we analyzed gene expression data and somatic DNA copy number changes by high-resolution array comparative genomic hybridization in tumors from 20 B-cell derived ARL (B-ARL) patients.

Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.

[MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology

[MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20216076.001).

[ISSN] 1944-7884

[Journal-full-title] Journal of acquired immune deficiency syndromes (1999)

[ISO-abbreviation] J. Acquir. Immune Defic. Syndr.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Activation of mTORC1 signaling pathway in AIDS-related lymphomas.

Using immunohistochemistry with antibodies against the phosphoserine residues in both S6rp and 4E binding protein 1, we identified the activation of the mammalian target of rapamycin (mTORC)1 pathway in 29 cases of AIDS-related lymphoma.

These cases represented a diverse spectrum of histological types of non-Hodgkin lymphoma (24 cases) and classic Hodgkin lymphoma (five cases).

mTORC1 was also activated in the hyperplastic but not involuted follicles of HIV-associated lymphadenopathy in eight cases, supporting the notion that mTORC1 activation is a common feature of transformed lymphocytes irrespective of either their reactive or malignant phenotype.

We also found that in B-cell lines that represent diffuse large B-cell lymphoma, Burkitt lymphoma, Epstein-Barr virus-infected lymphocytes, and human herpesvirus 8-positive primary effusion lymphoma, inhibitors of Syk, MEK, and, seemingly, phosphoinositide 3 kinases suppressed mTORC1 activation, in particular when these inhibitors were used in combination.

These findings indicate that AIDS-related lymphoma and other histologically similar types of lymphomas that are derived from transformed B lymphocytes may display clinical responses to inhibitors that directly target mTORC1 or, possibly, upstream activators of the mTORC1 pathway.

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Transpl Int. 2003 Mar;16(3):202-6 [12664217.001]

[Cites] EMBO J. 2002 Aug 1;21(15):4070-80 [12145207.001]

[Cites] J Biol Chem. 2003 Jun 13;278(24):21960-71 [12668683.001]

[Cites] J Biol Chem. 2003 Sep 26;278(39):37288-96 [12867426.001]

[Cites] Biochimie. 2003 Aug;85(8):763-9 [14585543.001]

[Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]

[Cites] Pediatr Transplant. 2004 Jun;8(3):243-8 [15176961.001]

[Cites] J Biol Chem. 1991 Aug 15;266(23):14846-9 [1869521.001]

[Cites] J Biol Chem. 1992 Apr 25;267(12):8613-9 [1569106.001]

[Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9107-11 [1409610.001]

[Cites] J Biol Chem. 1993 Jul 25;268(21):15900-5 [8340414.001]

[Cites] J Biol Chem. 1993 Nov 15;268(32):24442-8 [8226994.001]

[Cites] J Biol Chem. 1994 Feb 25;269(8):5918-25 [8119935.001]

[Cites] J Immunol. 1994 Jun 1;152(11):5429-37 [8189062.001]

[Cites] EMBO J. 1996 Oct 1;15(19):5256-67 [8895571.001]

[Cites] Immunol Lett. 1999 Jun 1;68(2-3):301-9 [10424436.001]

[Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]

[Cites] J Virol. 2005 May;79(9):5499-506 [15827164.001]

[Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]

[Cites] J Biol Chem. 2005 May 20;280(20):19937-47 [15760907.001]

[Cites] Nephrol Dial Transplant. 2005 Aug;20(8):1748-51 [15919698.001]

[Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]

[Cites] Microsc Res Tech. 2005 Nov;68(3-4):168-75 [16276515.001]

[Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]

[Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]

[Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]

[Cites] Br J Cancer. 2006 Jan 30;94(2):195-9 [16404421.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466-71 [16567633.001]

[Cites] Am J Kidney Dis. 2006 May;47(5):e67-72 [16632009.001]

[Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]

[Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]

[Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]

[Cites] J Biol Chem. 2006 Sep 15;281(37):26904-13 [16816403.001]

[Cites] Oncogene. 2006 Oct 16;25(48):6347-60 [17041621.001]

[Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]

[Cites] Lab Invest. 2007 Jan;87(1):29-39 [17075574.001]

[Cites] Transplant Proc. 2007 May;39(4):1267-71 [17524950.001]

[Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]

[Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]

[Cites] Transplant Proc. 2007 Jul-Aug;39(6):2036-7 [17692685.001]

[Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]

[Cites] Blood. 2008 Feb 15;111(4):2181-9 [18025151.001]

[Cites] Transpl Int. 2008 Jun;21(6):605-8 [18282244.001]

[Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]

[Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4285-90 [10759564.001]

[Cites] Cancer Res. 2000 Jul 1;60(13):3504-13 [10910062.001]

[Cites] Transplantation. 2003 May 27;75(10):1710-7 [12777861.001]

(PMID = 19608873.001).

[ISSN] 1525-2191

[Journal-full-title] The American journal of pathology

[ISO-abbreviation] Am. J. Pathol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA089194; United States / NIDCR NIH HHS / DE / R01 DE017337; United States / NCI NIH HHS / CA / R01-CA89194; United States / NIDCR NIH HHS / DE / R01-DE-017337

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Phospho-Specific; 0 / Multiprotein Complexes; 0 / Proteins; 0 / Transcription Factors; 0 / mechanistic target of rapamycin complex 1; 17885-08-4 / Phosphoserine; EC 2.7.1.1 / TOR Serine-Threonine Kinases

[Other-IDs] NLM/ PMC2716976

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas.

The normal counterpart of the neoplastic B cells in Burkitt lymphoma (BL) is still unclear.

However, most of these studies rely on cell lines or on a small series of cases.

To help clarify the cell of origin of BL, semi-nested polymerase chain reaction (PCR) was performed to amplify the VDJ rearrangements of the immunoglobulin heavy chain (V(H)) genes, and the resultant amplificates were sequenced for comparison with known germline V(H) segments.

The results of this approach revealed that all cases (15 endemic BL [eBL], 10 sporadic BL [sBL], and 6 AIDS-related BL) harbor mutated V(H) genes, with different mutation ranges among the 3 types of BL.

The eBL and AIDS-related forms showed considerably higher mutation rates than the sBL form (5.1%, 5.4%, and 1.5%, respectively).

The mutations in eBL and AIDS-related BL also showed signs of antigen selection, whereas no signs of antigen selection were found in sBL.

Given that one of the main differences between eBL and AIDS-related BL on the one hand and sBL on the other hand is the association with Epstein-Barr virus (EBV), we compared EBV-positive and EBV-negative BLs independently of their geographic origin and HIV status.

The different types of C-MYC translocation reported in BL may also be related to the different stages of B-cell maturation.

[MeSH-major] Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Genes, Immunoglobulin. Herpesvirus 4, Human

[MeSH-minor] Adolescent. Adult. Aged. B-Lymphocytes / pathology. Child. Child, Preschool. Gene Rearrangement. Germinal Center / pathology. Humans. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / genetics. Middle Aged. Mutation. Polymerase Chain Reaction. Sequence Analysis, DNA

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15840698.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Immunoglobulin Heavy Chains

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Burkitt's lymphoma of the duodenum in a patient with AIDS.

Non-Hodgkin's lymphoma of B-cell type is the second most common neoplasm after Kaposi's sarcoma, among patients with human immunodeficiency virus infection.

Most non-Hodgkin's lymphoma cases that are associated with acquired immunodeficiency syndrome involve extranodal sites, especially the digestive tract and the central nervous system.

We report a case of primary lymphoma of the duodenum in a patient with AIDS.

A complete diagnostic study including histological, immunohistochemical and virological analyses showed high-grade B-cell Burkitt's lymphoma.

[MeSH-major] Burkitt Lymphoma / diagnosis. Duodenal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17653472.001).

[ISSN] 0037-8682

[Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical

[ISO-abbreviation] Rev. Soc. Bras. Med. Trop.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CNS prophylaxis in lymphoma: who to target and what therapy to use.

The purpose of this article is to review the current data on the risk of CNS relapse in patients with lymphoma and the efficacy of CNS directed prophylactic therapy.

CNS relapse occurred in 30-50% of those with Burkitt lymphoma and acute lymphoblastic leukaemia/lymphoma prior to the introduction of intensified regimens that include CNS prophylaxis.

Most patients with AIDS-related-lymphoma receive a short course of intrathecal prophylaxis but a re-evaluation of type and targeting of CNS prophylaxis is needed.

Patients with diffuse large B-cell lymphoma (DLBCL) have a 5% overall risk of CNS relapse but a high risk sub-population can be identified on the basis of raised LDH and >1 extranodal site, testicular or primary breast involvement.

[MeSH-major] Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / prevention & control. Lymphoma / complications. Lymphoma / prevention & control

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16884838.001).

[ISSN] 0268-960X

[Journal-full-title] Blood reviews

[ISO-abbreviation] Blood Rev.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Scotland

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 151

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related cancer and severity of immunosuppression in persons with AIDS.

BACKGROUND: The incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer has been declining among persons with AIDS.

We investigated the association between cancer risk and CD4 cell count among such persons.

METHODS: Data from US AIDS registries were linked to local cancer registry data.

Cancer incidence per 100,000 person-years was determined for the 4-27 months from the onset of AIDS from January 1, 1990, through December 31, 1995--before highly active antiretroviral therapy (HAART) became available--and from January 1, 1996, through December 31, 2002.

The relationships between CD4 count at AIDS onset and cancer incidence were assessed by proportional hazards models.

RESULTS: Among 325,516 adults with AIDS, the incidence of Kaposi sarcoma was lower in 1996-2002 (334.6 cases per 100,000 person-years) than in 1990-1995 (1838.9 cases per 100,000 person-years), and the incidence of non-Hodgkin lymphoma followed a similar pattern (i.e., 390.1 cases per 100,000 person-years in 1996-2002 and 1066.2 cases per 100,000 person-years in 1990-1995).

In 1996-2002, for each decline in CD4 cell count of 50 cells per microliter of blood, increased risks were found for Kaposi sarcoma (hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.33 to 1.50), for central nervous system non-Hodgkin lymphoma subtypes (HR = 1.85, 95% CI = 1.58 to 2.16), and for non-central nervous system diffuse large B-cell lymphoma (HR = 1.12, 95% CI = 1.04 to 1.20) but not for non-central nervous system Burkitt lymphoma (HR = 0.93, 95% CI = 0.81 to 1.06).

After adjustment for age, race, and sex or mode of HIV exposure, the risks for Kaposi sarcoma (RR = 0.22, 95% CI = 0.20 to 0.24) and for non-Hodgkin lymphoma (RR = 0.40, 95% CI = 0.36 to 0.44) were lower in the period of 1996-2002 than in 1990-1995.

CONCLUSIONS: Both before and after HAART was available, CD4 count was strongly associated with risks for Kaposi sarcoma and non-Hodgkin lymphoma but not for cervical cancer and Burkitt lymphoma.

The decreasing incidences of most AIDS-associated cancers in persons with AIDS during the 1990s are consistent with improving CD4 counts after HAART introduction in 1996.

[MeSH-major] Acquired Immunodeficiency Syndrome / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology. Sarcoma, Kaposi / immunology

[MeSH-minor] Adolescent. Adult. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / immunology. Burkitt Lymphoma / virology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Female. Humans. Male. Middle Aged. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / immunology. Uterine Cervical Neoplasms / virology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17565153.001).

[ISSN] 1460-2105

[Journal-full-title] Journal of the National Cancer Institute

[ISO-abbreviation] J. Natl. Cancer Inst.

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphoproliferative disease.

Not long after the recognition of HIV as the causative agent of AIDS, it was evident that individuals infected with HIV developed lymphoma at a greater rate than the population at large.

Approximately two thirds of AIDS-related lymphoma (ARL) cases are categorized as diffuse large B-cell type, with Burkitt lymphomas comprising 25% and other histologies a much smaller proportion.

For patients with relapses, solid evidence points to the safety and utility of hematopoietic-cell transplantation as a salvage modality.

Coinfection with other viruses such as Epstein-Barr virus and Kaposi sarcoma-associated herpesvirus have led to the genesis of previously rare or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.

[MeSH-major] Lymphoma, AIDS-Related / therapy

[MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Transplantation. Humans. Lymphoproliferative Disorders / therapy. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16099881.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 100